Revolution Medicines (RVMD) Payables (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Payables of $80.5 million for Q1 2026, up 69.53% year-over-year from $47.5 million in Q1 2025, and up 24.64% quarter-over-quarter from $64.6 million in Q4 2025.
Revolution Medicines (RVMD) Payables (2019 - 2026) Analysis & Trends
Revolution Medicines' Payables history runs 8 years deep, the most recent figure standing at $80.5 million for Q1 2026.
- In Q1 2026, Payables rose 69.53% year-over-year to $80.5 million; the TTM figure through Mar 2026 stood at $80.5 million (up 69.53% YoY), while the FY2025 annual figure was $64.6 million, up 18.72% from the prior year.
- Payables for Q1 2026 stood at $80.5 million, up from $64.6 million in the prior quarter.
- The five-year high for Payables was $80.5 million in Q1 2026, with the low at $14.1 million in Q2 2022.
- The 5-year median for Payables is $29.8 million (2023), against an average of $40.0 million.
- The sharpest annual moves came in 2024 and 2025: Payables declined 17.45% in 2024, then jumped 206.06% in 2025.
- Revolution Medicines' Payables stood at $21.3 million in 2022, then jumped by 190.0% to $61.8 million in 2023, then slipped by 11.91% to $54.4 million in 2024, then climbed by 18.72% to $64.6 million in 2025, then climbed by 24.64% to $80.5 million in 2026.
- Business Quant data shows RVMD's Payables at $80.5 million in Q1 2026, $64.6 million in Q4 2025, and $74.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 25.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88.42 Mn |
| Mar 31, 2026 | 80.54 Mn |
| Dec 31, 2025 | 64.62 Mn |
| Sep 30, 2025 | 74.85 Mn |
| Jun 30, 2025 | 56.76 Mn |
| Mar 31, 2025 | 47.51 Mn |
| Dec 31, 2024 | 54.43 Mn |
| Sep 30, 2024 | 24.46 Mn |
| Jun 30, 2024 | 29.32 Mn |
| Mar 31, 2024 | 32.38 Mn |
| Dec 31, 2023 | 61.79 Mn |
| Sep 30, 2023 | 29.63 Mn |
| Jun 30, 2023 | 29.78 Mn |
| Mar 31, 2023 | 19.91 Mn |
| Dec 31, 2022 | 21.31 Mn |
| Sep 30, 2022 | 24.38 Mn |
| Jun 30, 2022 | 14.07 Mn |
| Mar 31, 2022 | 14.17 Mn |
| Dec 31, 2021 | 14.06 Mn |
| Sep 30, 2021 | 10.49 Mn |